Targeting Neuro-Inflammation & Neuro-Ischemia at clinical scale.

Apexaa is advancing late-stage therapeutics for the most under-served disorders of the central nervous system — from acute ischemic injury to chronic neuro-inflammatory disease.

Therapeutic Focus

Late-stage neurology, built for clinical impact.

Phase III

Pivotal-Stage Pipeline

Lead programs in late-stage clinical trials, advancing toward registration.

Neuro-Inflammation

Modulating CNS Immunity

Targeting the inflammatory cascades that drive neuronal injury and progressive disease.

Neuro-Ischemia

Protecting Infarct Tissue

Therapeutics designed to protect tissue and recover function after ischemic insult.

More information coming soon

Pipeline detail, clinical-trial programs, and team information will be published shortly.